Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466415 | 0.73 | — | — | |
| SCHEMBL11633944 | 0.73 | GPR3 (0.41) | GPR3MEN1KMT2ANOX1CA12 | |
| SCHEMBL8024079 | 0.73 | GPR3 (0.41) | GPR3MEN1KMT2ANOX1CA12 | |
| SCHEMBL308829 | 0.73 | GPR3 (0.41) | GPR3MEN1KMT2ANOX1CA12 | |
| SCHEMBL30430615 | 0.73 | GPR3 (0.41) | GPR3MEN1KMT2ANOX1CA12 | |
| SCHEMBL10860629 | 0.73 | GPR3 (0.41) | GPR3MEN1KMT2ANOX1CA12 | |
| SCHEMBL11638030 | 0.73 | GPR3 (0.41) | GPR3MEN1KMT2ANOX1CA12 | |
| SCHEMBL11036902 | 0.70 | GPR3 (0.55) | GPR3MEN1KMT2ANOX1CA12 | |
| SCHEMBL30429636 | 0.70 | CA12 (0.41) | GPR3MEN1KMT2ANOX1CA12 | |
| SCHEMBL9317135 | 0.68 | GPR3 (0.37) | GPR3MEN1KMT2ANOX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | claimed |
| EP-3323414-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-1945617-B1 | HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS | MERCK SHARP & DOHME (US) | 2012-12-26 | — | — | EP | claimed |
| US-8093354-B2 | Process for preparing glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-20110060122-A1 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2011-03-10 | — | — | US | claimed |
| US-20090291965-A1 | Histone Deacetylase Inhibitors With Aryl-Pyrazolyl-Motifs | MERCK SHARP & DOHME LLC | 2009-11-26 | — | — | US | claimed |
| US-20080227963-A1 | Process for preparing glycopeptide phosphonate derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2008-09-18 | — | — | US | claimed |
| EP-1419174-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE DERIVATIVES | Theravance, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003029270-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2003-04-10 | — | — | WO | claimed |
| US-20030069391-A1 | Process for preparing glycopeptide phosphonate derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2003-04-10 | — | — | US | claimed |
| US-20030045457-A1 | Process for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2003-03-06 | — | — | US | claimed |
| WO-2003018607-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE DERIVATIVES | THERAVANCE, INC. (US) | 2003-03-06 | — | — | WO | claimed |
| EP-0460679-B1 | Endothelin antagonistic peptide derivatives | BANYU PHARMA CO LTD (JP) | 1998-10-28 | — | — | EP | claimed |
| US-5470833-A | Vasodilators, bronchodilators | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-11-28 | — | — | US | claimed |
| US-5444152-A | Vasolidator or bronchodilator | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-22 | — | — | US | claimed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | claimed |
| EP-0460679-A2 | Endothelin antagonistic peptide derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-12-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045457-A1 | Process for preparing glycopeptide derivatives | GYPA, VIP, OGT | GPR3 2290/4885MEN1 3165/4885KMT2A 4121/4885 |
| US-20080227963-A1 | Process for preparing glycopeptide phosphonate derivatives | PGLS, GYPA, PAG1 | GPR3 2622/4885MEN1 2435/4885KMT2A 4252/4885 |
| US-20110060122-A1 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PGLS, GYPA, PAG1 | GPR3 2622/4885MEN1 2435/4885KMT2A 4252/4885 |
| US-20090291965-A1 | Histone Deacetylase Inhibitors With Aryl-Pyrazolyl-Motifs | HDAC1, HDAC3, HDAC5 | GPR3 2968/4885MEN1 4602/4885KMT2A 84/4885 |
| US-20030069391-A1 | Process for preparing glycopeptide phosphonate derivatives | PGLS, GYPA, PAG1 | GPR3 2622/4885MEN1 2435/4885KMT2A 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.